Biotech entity
All 1 tracked stories fall under one category: acquisition. Neuritek Therapeutics, Inc. is most often covered alongside Wellgistics Health Inc., which appears in 1 of these 1 story. The tracked stories average 2 original sources each. Neuritek Therapeutics, Inc. appears in 1 tracked Biotech story from March 23, 2026.
Last mentioned: Mar 23, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: acquisition. Neuritek Therapeutics, Inc. is most often covered alongside Wellgistics Health Inc., which appears in 1 of these 1 story. The tracked stories average 2 original sources each. Neuritek Therapeutics, Inc. appears in 1 tracked Biotech story from March 23, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 11 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Neuritek Therapeutics, Inc.. Shared-story counts are live from our verified record — not editorial picks.
Wellgistics Health Inc. has entered into a non-binding Letter of Intent to acquire Neuritek Therapeutics for $105 million. The deal marks a significant strategic pivot for Wellgistics into the high-growth neurological and psychiatric drug development sector.
Neuritek Therapeutics, Inc. is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
